New podcast features world-class scientists and doctors sharing late-breaking Alzheimer’s and dementia research in plain language for families and caregivers.
CLARKSBURG, Md., June 11, 2026—BrightFocus Foundation today announced the launch of Let’s Talk Alzheimer’s, a new podcast that brings insightful, actionable conversations about Alzheimer’s disease and brain health to listeners in an accessible, on-demand audio/video format.
Produced by BrightFocus Foundation’s Alzheimer’s Disease Research program, the podcast features content adapted from BrightFocus’ highly popular Zoom In on Dementia & Alzheimer’s series, which has garnered over 7 million views to date.
The first three episodes, released today, explore cutting-edge topics including eligibility and usage information for the new disease-modifying treatments Leqembi and Kisunla (Dr. Armen Moughamian, Sutter Health); how to recognize the earliest signs and symptoms of Alzheimer’s (Dr. Sharon Cohen, University of Toronto); and how modifying certain lifestyle factors have been proven to substantially improve brain health (Dr. Laura Baker, Wake Forest University School of Medicine). Previous guests have included leading researchers from Washington University in St. Louis, Harvard, Mayo Clinic, and Barrow Neurological Institute. New episodes will be released bi-weekly and available on major podcast platforms, including Apple Podcasts, Spotify, and YouTube.
Let’s Talk Alzheimer’s is hosted by Nancy Keach, senior vice president at BrightFocus Foundation and an award-winning documentary film producer. Episodes feature internationally recognized Alzheimer’s researchers, physicians, and clinicians covering timely topics such as early diagnosis, treatment options, non-pharmacological interventions, brain health research, active clinical trials, and practical guidance—helping individuals, families, and caregivers make sense of an often overwhelming journey.
“Families affected by Alzheimer’s disease are seeking clear, trustworthy information they can easily access and understand,” said Stacy Pagos Haller, president and CEO of BrightFocus Foundation. “By adapting our popular, live Zoom In conversations to the podcast format, we’re making these important expert insights available to even more people wherever and whenever they choose to listen.”
“Alzheimer’s research is advancing rapidly, and there is tremendous interest in understanding what these discoveries mean for individuals and families,” said Haller. “This podcast helps translate complex science into engaging, approachable conversations people can listen to anytime.”
To listen and learn more, visit BrightFocus.org/LetsTalkAlzheimers.
BrightFocus thanks the sponsors of Let’s Talk Alzheimer’s for making this program free and accessible to all: Lilly, Biogen, Eisai, and Genentech.
BrightFocus Foundation is a leading provider of free educational resources on Alzheimer’s disease, macular degeneration, and glaucoma, reaching millions of individuals each year through trusted health information and public awareness initiatives.
Among its signature programs are Zoom In on Dementia & Alzheimer’s, Macular Chats, and Glaucoma Chats, presented in partnership with the American Glaucoma Society—free monthly discussions featuring leading scientists, physicians, and vision experts. Through expert-led live webinars, podcasts, articles, fact sheets, and community programs, BrightFocus is dedicated to connecting people with timely, evidence-based information and practical guidance to support brain and vision health.
Media Contact
Julia Roth
jroth@brightfocus.org
BrightFocus Foundation is a premier global nonprofit funder of research to defeat Alzheimer’s, macular degeneration, and glaucoma. Since its inception more than 50 years ago, BrightFocus and its flagship research programs—Alzheimer’s Disease Research, Macular Degeneration Research, and National Glaucoma Research—has awarded more than $330 million in research grants to scientists around the world, catalyzing thousands of scientific breakthroughs, life-enhancing treatments, and diagnostic tools. We also share the latest research findings, expert information, and resources to empower the millions impacted by these devastating diseases. Learn more at brightfocus.org.
Disclaimer: The information provided here is a public service of BrightFocus Foundation and is not intended to constitute medical advice. Please consult your physician for personalized medical, dietary, and/or exercise advice. Any medications or supplements should only be taken under medical supervision. BrightFocus Foundation does not endorse any medical products or therapies.
Auvelity, developed by Axsome Therapeutics, was approved today by the U.S. Food & Drug Administration (FDA) for the treatment of Alzheimer’s disease agitation, a common and challenging symptom that affects 40 to 60 percent of people living with Alzheimer’s.
BrightFocus Foundation’s VP of Scientific Affairs helped set national research priorities at the federal Alzheimer’s Disease-Related Dementias Summit, influencing how billions in NIH funding will advance dementia research and care.
New formulation of Leqembi allows weekly at-home injections, reducing the need for hospital visits.
From lifestyle changes that protect memory and cutting‑edge blood tests to promising long‑term treatment results, promising new developments in Alzheimer’s research were unveiled at the 2025 Alzheimer’s Association International Conference (AAIC) in Toronto.
Every Donation is a Step Forward in the Fight Against Alzheimer’s
Your donation powers cutting-edge research and helps scientists explore new treatments. Help bring us closer to a cure and provide valuable information to the public.
Donate Today
